Verily Raises $300 Million to Expand AI-Driven Healthcare Platform
Verily, a healthtech company majority-owned by Alphabet, secured $300 million in funding to accelerate its AI for healthcare strategy and scale precision medicine capabilities across clinical research and care delivery.
Series X Capital led the funding round. New and existing investors include UCHealth, the University of Colorado Anschutz, and Alphabet, which retained a minority stake.
The company restructured from an LLC to a corporation and rebranded as Verily Health. The capital will fund development of its AI platforms-Verily Pre and Verily Me-designed to help healthcare organizations harmonize data, model outcomes, and deploy intelligence into research and clinical workflows.
Strategic Partnerships Accelerate Development
Verily is integrating Nvidia's AI technology stack into its Pre platform to speed research analysis and accelerate development of generative AI and LLM agents for clinical care and research.
The company also announced partnerships with Samsung to integrate Galaxy Watch biomarker development into its Pre platform for clinical research, and with Salesforce to integrate Pre with Agentforce Health for enterprise precision health solutions.
Focus on Precision and Personalization
Stephen Gillett, CEO of Verily, said the funding represents progress toward bringing "precision health to everyone." He emphasized that customers need solutions combining clinical rigor with AI to deliver personalized healthcare at scale.
The company plans to build scalable AI infrastructure and data systems supporting precision medicine across research, care delivery, and population health management.
Your membership also unlocks:
